SBIR/STTR Research Award
THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A VESIVAX PLATFORM-BASED LIPOSOMAL FORMULATION THAT WILL EFFICIENTLY DISPLAY THE HIV IMMUNOGEN.
Award amount
$299,993Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R1JMHFESEKD5
- Solicitation number
- Not reported
- Topic code
- 77
Research abstract
Th is proposal aim to develop a VesiVax® platform-based liposomal formulation that will efficiently display the HIV immunogen, HIV Env gp120 (A244) antigen, and elicit a potent neutralizing antibody response. The HIV Env(A244) antigen will be prepared as HIV-Env(A244)-Cys or HIV-Env(A244gp41e)-HD. The purified antigens will be formulated with VesiVax® liposomes containing the approved Toll-like Receptor 4 agaonist monophosphoryl lipid A. These VesiVax® HIV-Env(A244) immunogen liposome formulations will be tested in mice to identify the formulation that can stimulate the strongest anti-HIV-Env(A244) response
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense